--- title: "人保健康 (Q1) 季度盈利强劲，但受降低的指引影响" description: "Humana 报告显示，第一季度业绩强劲，超出了收入和盈利的预期。公司的战略增长举措，包括扩大 CenterWell 业务板块，为其成功做出了贡献。然而，Humana 降低了全年 GAAP 每股盈利指引，反映出在应对运营和市场挑战时的谨慎态度。投资者应关注医疗保险计划成员增长、医疗补助扩张以及 CenterWell 业务板块的发展" type: "news" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/202936318.md" published_at: "2024-04-26T14:51:14.000Z" --- # 人保健康 (Q1) 季度盈利强劲，但受降低的指引影响 > Humana 报告显示，第一季度业绩强劲，超出了收入和盈利的预期。公司的战略增长举措，包括扩大 CenterWell 业务板块，为其成功做出了贡献。然而，Humana 降低了全年 GAAP 每股盈利指引，反映出在应对运营和市场挑战时的谨慎态度。投资者应关注医疗保险计划成员增长、医疗补助扩张以及 CenterWell 业务板块的发展 Health insurance giant **Humana** (HUM -0.89%) released its first-quarter earnings for 2024 on Wednesday, dazzling investors and analysts alike. It not only beat analysts' estimates for both earnings and revenue but also showcased its ongoing strategic growth endeavors. Metrics Q1 2024 Analyst Estimates Q1 2023 Change (YOY) Revenue $29.6 billion $28.5 billion $26.7 billion 10.7% Adjusted EPS $7.23 $6.12 $9.38 \-22.9% GAAP EPS $6.11 N/A $9.87 \-38.1% Operating expenses $28.4 billion N/A $25 billion +13.4% Operating cost ratio 10.4% N/A 11.2% +80 bps Analyst source: FactSet. YOY = Year over year. BPS = Basis points. GAAP = Generally accepted accounting principles. ## Humana's profile and strategic focus Humana stands at the forefront of the health insurance industry, with its core focus on the Medicare Advantage program. This program constitutes a significant portion of Humana's revenue. Through comprehensive health insurance benefits, Humana caters to Medicare-eligible individuals, blending wellness programs, chronic care management, and care coordination under one roof. Moreover, Humana's strategic expansion into the CenterWell segment marks its ambition beyond traditional insurance. CenterWell encompasses pharmacy solutions, primary care, and home solutions, aiming for innovation in healthcare services and operational efficiencies. ## Quarterly highlights This quarter saw Humana's adjusted EPS climb to $7.23, primarily driven by higher-than-expected revenue and operational efficiencies. The company's revenue surged to $29.6 billion, attributed to robust performance in its insurance segment and strategic expansions in Medicaid across multiple states. Besides financial performance, Humana reported a significant increase in its growth estimate for individual Medicare Advantage membership. It revised its annual growth expectation to 150,000, an increase of 50,000 over the previous outlook. That would be a 2.8% increase over 2023 totals. This upward adjustment highlights Humana's successful strategy in attracting and retaining members in this critical segment. Additionally, Humana's focus on the CenterWell segment brought about promising developments. CenterWell quarterly revenue of $4.82 billion was up 6.9% year over year. From expanding home solutions to enhancing primary care offerings, these strategic moves aim to diversify Humana's revenue streams and solidify its footprint in the healthcare services market. The quarter was not without its challenges, as the company saw total operating expenses of $28.4 billion, up 13.4% year over year. The increase was attributed to higher overall benefits expenses and operating costs. The operating cost ratio, however, improved by 80 basis points year over year to 14.6%, thanks to rising scale and cost efficiencies. ## Looking ahead For the remainder of 2024, Humana has adjusted its full-year GAAP EPS guidance to approximately $13.93, a decrease from its initial forecast of $14.87. However, it maintains an optimistic view on the adjusted EPS, holding steadfast at $16. This outlook reflects Humana's cautious yet hopeful perspective on navigating operational and market challenges ahead. Investors should monitor Humana's efforts in member growth within its Medicare Advantage programs, its expansion into Medicaid, and further developments in the CenterWell segment. These areas, combined with Humana's adaptability to changing healthcare landscapes, will be crucial for its continuing success. ### Related Stocks - [HUM.US - 休曼纳](https://longbridge.com/zh-CN/quote/HUM.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | HUMANA INC SEC 10-K Report | Humana Inc. has released its 2025 Form 10-K report, highlighting a 10.1% increase in total revenues to $129.7 billion, d | [Link](https://longbridge.com/zh-CN/news/276371705.md) | | Forecasting The Future: 15 Analyst Projections For Humana | In the latest quarter, 15 analysts provided mixed ratings for Humana (NYSE:HUM), with an average 12-month price target o | [Link](https://longbridge.com/zh-CN/news/276258083.md) | | Are Wall Street Analysts Predicting Keysight Technologies Stock Will Climb or Sink? | Are Wall Street Analysts Predicting Keysight Technologies Stock Will Climb or Sink? | [Link](https://longbridge.com/zh-CN/news/276353077.md) | | NEOS Investment Management LLC Raises Stake in Keysight Technologies Inc. $KEYS | NEOS Investment Management LLC increased its stake in Keysight Technologies Inc. by 44.3% in Q3, now holding 18,730 shar | [Link](https://longbridge.com/zh-CN/news/276440516.md) | | Readystate Asset Management LP Sells 288,480 Shares of Celldex Therapeutics, Inc. $CLDX | Readystate Asset Management LP has significantly reduced its stake in Celldex Therapeutics, Inc. by 86.1%, selling 288,4 | [Link](https://longbridge.com/zh-CN/news/276326472.md) | --- > **免责声明**：本文内容仅供参考，不构成任何投资建议。